Zevra Therapeutics (NASDAQ:ZVRA) Given New $25.00 Price Target at Maxim Group

Zevra Therapeutics (NASDAQ:ZVRA) had its price objective boosted by Maxim Group from $18.00 to $25.00 in a research note issued to investors on Tuesday morning, Marketbeat reports. Maxim Group currently has a buy rating on the stock.

Other analysts have also recently issued research reports about the company. HC Wainwright boosted their target price on Zevra Therapeutics from $18.00 to $20.00 and gave the stock a buy rating in a report on Friday, September 20th. Cantor Fitzgerald reiterated an overweight rating on shares of Zevra Therapeutics in a research note on Wednesday, August 14th. Canaccord Genuity Group cut their target price on shares of Zevra Therapeutics from $24.00 to $22.00 and set a buy rating on the stock in a research note on Wednesday, September 18th. Finally, William Blair raised shares of Zevra Therapeutics to a strong-buy rating in a research report on Friday, August 30th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Zevra Therapeutics currently has a consensus rating of Buy and a consensus target price of $21.00.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA opened at $8.27 on Tuesday. The company has a market cap of $346.12 million, a P/E ratio of -6.13 and a beta of 1.94. The firm’s 50 day moving average is $7.10 and its two-hundred day moving average is $5.73. Zevra Therapeutics has a fifty-two week low of $3.89 and a fifty-two week high of $8.95. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.80.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. The firm had revenue of $4.45 million during the quarter, compared to analysts’ expectations of $4.08 million. During the same period last year, the business posted ($0.15) earnings per share. Analysts expect that Zevra Therapeutics will post -1.58 EPS for the current year.

Insider Activity

In other news, Director John B. Bode purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, July 12th. The shares were purchased at an average price of $5.87 per share, with a total value of $58,700.00. Following the purchase, the director now directly owns 30,000 shares of the company’s stock, valued at approximately $176,100. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders bought 22,000 shares of company stock worth $140,340. 2.40% of the stock is currently owned by company insiders.

Institutional Trading of Zevra Therapeutics

Large investors have recently modified their holdings of the business. Jump Financial LLC acquired a new position in shares of Zevra Therapeutics in the fourth quarter worth about $217,000. Armistice Capital LLC purchased a new stake in Zevra Therapeutics during the 4th quarter worth approximately $1,755,000. Jacobs Levy Equity Management Inc. increased its holdings in Zevra Therapeutics by 102.4% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after purchasing an additional 17,557 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Zevra Therapeutics during the 4th quarter valued at approximately $177,000. Finally, Focus Financial Network Inc. ADV acquired a new stake in shares of Zevra Therapeutics during the fourth quarter worth approximately $141,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.